Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.47 |
| ▸ | RORB | Q92753 | 3/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290810 | 0.86 | AKR1C3 (0.47) | AKR1C3AKR1C2RORBRORCPTPN5 | |
| SCHEMBL16290837 | 0.82 | PDGFRB (0.43) | KDM4EALDH1A1HPGDSCN9ACYP2C9 | |
| SCHEMBL16290948 | 0.81 | AKR1C3 (0.48) | AKR1C3AKR1C2RORBRORCPTPN5 | |
| SCHEMBL16290880 | 0.80 | MAPK10 (0.44) | RORBRORCSMN1; SMN2SCN9A | |
| SCHEMBL1133453 | 0.76 | PTPN5 (0.69) | AKR1C3AKR1C2RORBRORCPTPN5 | |
| SCHEMBL22009314 | 0.76 | PTPN5 (0.54) | AKR1C3AKR1C2RORBRORCPTPN5 | |
| SCHEMBL16290723 | 0.75 | MAOA (0.54) | AKR1C3AKR1C2RORBRORCNPSR1 | |
| SCHEMBL16068206 | 0.74 | PTPN5 (0.55) | AKR1C3AKR1C2RORBRORCPTPN5 | |
| SCHEMBL16806029 | 0.73 | AKR1C3 (0.51) | AKR1C3AKR1C2RORBRORCPTPN5 | |
| SCHEMBL3786711 | 0.72 | RORB (0.50) | AKR1C3AKR1C2RORBRORCPTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042917-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-12139496-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20210253597-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253597-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-10947251-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947251-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3774801-A1 | FUSED RING HYDRO-PYRIDO COMPOUNDS AS SODIUM CHANNEL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936494-A | Substituted hydro-pyrido-azines as sodium channel inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20190300544-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| WO-2019191702-A1 | SUBSTITUTED HYDRO-PYRIDO-AZINES AS SODIUM CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160046626-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2016-02-18 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212182-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014201173-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2014201206-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042917-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | AKR1C3 30/4885AKR1C2 184/4885RORB 226/4885 |
| US-20190300544-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | AKR1C3 30/4885AKR1C2 184/4885RORB 226/4885 |
| US-20140371201-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | AKR1C3 2494/4885AKR1C2 2609/4885RORB 3394/4885 |
| US-20210253597-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | AKR1C3 30/4885AKR1C2 184/4885RORB 226/4885 |
| US-20160046626-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | SCN7A, TRPV1, TRPV5 | AKR1C3 2494/4885AKR1C2 2609/4885RORB 3394/4885 |
| US-10947251-B2 | Therapeutic compounds and methods of use thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | AKR1C3 30/4885AKR1C2 184/4885RORB 226/4885 |
| US-12139496-B2 | Therapeutic compounds and methods of use thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | AKR1C3 30/4885AKR1C2 184/4885RORB 226/4885 |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | AKR1C3 2350/4885AKR1C2 2132/4885RORB 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.